It is well-known that hydroxychloroquine (HCQ) treats malaria, systemic lupus erythematosus, and rheumatoid arthritis in women for its immunomodulatory and anti-inflammatory action. Additionally, HCQ was used in cases with refractory antiphospholipid syndrome. HCQ safety was reinforced in pregnant women owing to insignificant reports of adverse pregnancy outcomes and major congenital malformation. Recently, HCQ was tested in cases with chronic placental inflammation with a promising result of increased life birth; however, its benefit needs further validation. We aimed to highlight the recent updates for HCQ use in various conditions in pregnancy.
Keywords: Antiphospholipid syndrome; COVID-19; Chronic placental inflammation; Hydroxychloroquine; Preeclampsia; Pregnancy.
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.